Replies to post #7321 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[midastouch017]

Conclusions

[From the article]

The US launch of FDA-approved Consensi will be formally announced in May based on intelligence gathered in LinkedIn. This will be a significant catalyst for the stock.
The China and Korea commercial launch announcement should be forthcoming. This was highlighted in the May 8, 2020 filining with the SEC.
The Consensi US launch will be significant because its commercial partner Burke therapeutics is already filling pre-orders for this drug and has hired over 50 pharma reps with the goal of hiring 200 to cover the entire US
As a result of Consensi's commercialization plan, the Company expects to receive aggregate milestone and royalty revenues of between $28 million and $36 million from 2020 through 2022.
With the cash on hand as reported on April 30, 2020 the company is funded to 3Q 2021. This runway will be extended significantly with revenues derived from US Consensi sales starting in May 2020.
The company will announce Phase 1 results from its CM-24 candidate in combination with Bryston Myers Squib Opdivo at ASCO 2020 on May 29, 2020.
CM-24 has the potential to treat recurrent and advanced stage cancers including ovarian, colorectal, melanoma, lung, bladder and gastric cancers. The company's Phase I/II trial design could result in a strong display of the drug's efficacy to the benefit of patients and their families and potential lucrative partnerships.
The company plans to begin NT-219 clinical trials in 1H 2020 per the May 28, 2020 filining with the SEC.
The potential for NT-219 to be effective across several oncology therapies is what makes it a potential blockbuster drug. A great example is NT-219’s potential to convert non-responders to responders with Merck's Keytruda. Positive results in early clinical trails could result in significant partnerships with large pharma.
I recommend that those interested in investing in KTOV shares to read carefully the risks and uncertainties of doing so as detailed in the most recent company filings with the SEC.

Disclosure: I am/we are long KTOV.

:-)